UBE2N and prostate cancer: To explore the role of Wnt/β-catenin signaling in the functional mechanism of UBE2N, PC3 prostate cancer cells were overexpressed UBE2N (Fig. 4A and B) and treated with or without XAV939, an inhibitor for the Wnt/β-catenin pathway.